Overview
- Provide up-to-date information on approaches to the discovery of treatments for cognitive deficits in schizophrenia
- Provide information on promising new targets for therapeutics in the treatment of schizophrenia
- Describe potential use of adjunctive co-treatments for use together with traditional antipsychotics
- Includes supplementary material: sn.pub/extras
Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 213)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents(14 chapters)
About this book
Reviews
From the reviews:
“The target audience … is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. … This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a ‘one disease’ perspective.” (Michael Joel Schrift, Doody's Book Reviews, March, 2013)Editors and Affiliations
-
Dept. Psychiatry, University of California San Diego, La Jolla, USA
Mark A. Geyer
-
Institut für Pharmakologie, Universität, Neuroscience Research, Abbott GmbH & Co. KG, Ludwigshafen, Germany
Gerhard Gross
Bibliographic Information
Book Title: Novel Antischizophrenia Treatments
Editors: Mark A. Geyer, Gerhard Gross
Series Title: Handbook of Experimental Pharmacology
DOI: https://doi.org/10.1007/978-3-642-25758-2
Publisher: Springer Berlin, Heidelberg
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag Berlin Heidelberg 2012
Hardcover ISBN: 978-3-642-25757-5Published: 02 October 2012
Softcover ISBN: 978-3-642-43809-7Published: 09 November 2014
eBook ISBN: 978-3-642-25758-2Published: 01 October 2012
Series ISSN: 0171-2004
Series E-ISSN: 1865-0325
Edition Number: 1
Number of Pages: X, 458
Topics: Pharmacology/Toxicology, Pharmacy, Psychopharmacology, Biological Psychology